Introduction
In vitro transcription (IVT) is the enzymatic process that produces messenger RNA (mRNA) from a DNA template. Since the global success of COVID-19 mRNA vaccines, IVT has become one of the most strategically important technologies in biopharmaceutical manufacturing. Today, mRNA is being developed for vaccine platforms, therapeutic proteins, cancer immunotherapy, gene editing, and regenerative medicine.
This article provides a comprehensive overview of IVT and mRNA synthesis — covering the core process, key raw materials, quality considerations, and emerging applications. Whether you are a researcher optimizing IVT yield, a process development scientist scaling up production, or a procurement professional sourcing critical raw materials, this guide is designed for you.
1. What Is IVT and How Does It Work?
1.1 Definition
In vitro transcription (IVT) is a cell-free enzymatic reaction that synthesizes RNA from a DNA template using an RNA polymerase. The process occurs in a controlled reaction buffer and does not require living cells.
1.2 Core Reaction
The IVT reaction requires four essential components:
| Component | Function |
|---|---|
| DNA Template | Provides the sequence to be transcribed |
| RNA Polymerase | Catalyzes RNA synthesis |
| NTPs | Building blocks of RNA |
| Reaction Buffer | Provides optimal pH, ions, and cofactors |
1.3 mRNA Structure
A mature mRNA molecule contains several key structural elements:
| Element | Function |
|---|---|
| 5′ Cap | Protects mRNA, enables translation initiation |
| 5′ UTR | Regulates translation efficiency |
| Coding Sequence (CDS) | Encodes the target protein |
| 3′ UTR | Affects mRNA stability and translation |
| Poly(A) Tail | Enhances stability and translation efficiency |
Each of these elements must be carefully designed and synthesized to produce functional mRNA.
2. Key Raw Materials for IVT
2.1 DNA Template
| Template Type | Description | Key Considerations |
|---|---|---|
| Linearized Plasmid DNA | Most common; linearized by restriction digestion | Must be completely linearized |
| PCR Amplicon | Generated with promoter-tagged primers | Rapid; suitable for small-scale |
| Synthetic DNA Fragment | Chemically synthesized dsDNA | High flexibility |
The DNA template must contain a promoter sequence (T7, T3, or SP6) upstream of the target gene.
2.2 RNA Polymerase
| Enzyme | Source | Key Features |
|---|---|---|
| T7 RNA Polymerase | Bacteriophage T7 | High processivity; most widely used |
| T3 RNA Polymerase | Bacteriophage T3 | Different promoter specificity |
| SP6 RNA Polymerase | Bacteriophage SP6 | Lower yield; specialized applications |
T7 RNA polymerase is the industry standard for mRNA synthesis.
2.3 Nucleoside Triphosphates (NTPs)
| Nucleotide | CAS Number | Function |
|---|---|---|
| ATP | 56-65-5 | Adenine nucleotide |
| GTP | 86-01-1 | Guanine nucleotide |
| CTP | 65-47-4 | Cytosine nucleotide |
| UTP | 63-39-8 | Uracil nucleotide |
2.4 Modified Nucleotides
Modified nucleotides are critical for therapeutic mRNA to reduce immunogenicity and enhance stability.
| Modified Nucleotide | CAS Number | Function |
|---|---|---|
| N1-Methylpseudouridine-5′-triphosphate | 1428903-59-6 | Reduces immunogenicity; used in COVID-19 vaccines |
| Pseudouridine-5′-triphosphate | 1175-34-4 | Natural modification |
| 5-Methoxyuridine-5′-triphosphate | 1418240-47-8 | Enhances translation |
| 5-Methylcytidine-5′-triphosphate | 32747-18-5 | Reduces immunogenicity |
2.5 Capping Agents
| Capping Agent | Description | Key Features |
|---|---|---|
| CleanCap AG | Trinucleotide cap analog | High efficiency; Cap 1 structure |
| ARCA | Anti-Reverse Cap Analog | Prevents reverse capping |
| mCap Analog | Standard cap analog | Lower efficiency |
2.6 Buffer Components
| Component | CAS Number | Function | Typical Concentration |
|---|---|---|---|
| Tris-HCl (pH 8.0) | 1185-53-1 | pH buffer | 40 mM |
| HEPES-KOH (pH 7.5) | 7365-45-9 | Alternative buffer | 40 mM |
| Magnesium Acetate | 142-72-3 | Cofactor | 8-12.5 mM |
| DTT | 3483-12-3 | Reducing agent | 5-10 mM |
| Spermidine | 124-20-9 | Enhances transcription | 2 mM |
2.7 Auxiliary Enzymes
| Component | Function |
|---|---|
| RNase Inhibitor | Protects RNA from degradation |
| Pyrophosphatase | Prevents pyrophosphate inhibition |
| DNase I | Removes DNA template after transcription |
3. IVT Process Workflow
| Step | Operation | Key Parameters |
|---|---|---|
| 1. Template Preparation | Linearize plasmid DNA | Complete linearization |
| 2. IVT Reaction | Combine template, polymerase, NTPs, buffer | 37°C, 1-4 hours |
| 3. DNase Treatment | Remove DNA template | 37°C, 15-30 minutes |
| 4. Purification | Remove enzymes and unincorporated NTPs | LiCl precipitation or spin column |
| 5. Capping | Add 5′ cap (co-transcriptional or post-transcriptional) | CleanCap or enzymatic capping |
| 6. Poly(A) Tailing | Add poly(A) tail | Enzymatic or template-encoded |
| 7. Quality Control | Assess purity, integrity, and capping efficiency | Gel electrophoresis, HPLC |
4. Quality Control for mRNA
| Parameter | Method | Acceptance Criteria |
|---|---|---|
| Purity | A260/280 | 1.8-2.1 |
| Integrity | Gel electrophoresis or Bioanalyzer | Single sharp band |
| Capping Efficiency | HPLC or LC-MS | >90% for therapeutic mRNA |
| Residual DNA | qPCR | <10 ng/mg RNA |
| Residual NTPs | HPLC | Below specified limits |
| Endotoxin | LAL assay | <5 EU/mg for injectables |
5. Applications of IVT mRNA
| Application | Description | Examples |
|---|---|---|
| mRNA Vaccines | Encode antigens for immune response | COVID-19, influenza, RSV, cancer vaccines |
| Therapeutic Proteins | Replace missing or defective proteins | Enzyme replacement, monoclonal antibodies |
| Cancer Immunotherapy | Express tumor antigens or immune modulators | Personalized cancer vaccines, CAR-T |
| Gene Editing | Deliver CRISPR/Cas9 components | Gene correction, disease modeling |
| Regenerative Medicine | Reprogram cells for tissue repair | iPSC generation, organ regeneration |
6. Challenges and Future Trends
6.1 Current Challenges
| Challenge | Description |
|---|---|
| Stability | mRNA is inherently unstable; requires cold chain |
| Delivery | Efficient delivery to target cells remains challenging |
| Immunogenicity | Unmodified mRNA triggers innate immune response |
| Manufacturing Cost | High cost of raw materials (modified NTPs, capping agents) |
| Scalability | Large-scale production requires optimized processes |
6.2 Future Trends
| Trend | Description |
|---|---|
| Self-Amplifying mRNA | Lower doses; prolonged expression |
| Circular RNA | Enhanced stability; longer half-life |
| Next-Generation LNPs | Improved targeting; reduced side effects |
| Lyophilized mRNA | Room-temperature stable formulations |
| AI-Guided Sequence Design | Optimized UTRs and codons for enhanced expression |
7. Frequently Asked Questions (FAQ)
Q1: What is the difference between co-transcriptional capping and enzymatic capping?
Co-transcriptional capping incorporates a cap analog (e.g., CleanCap AG) directly into the IVT reaction, producing capped mRNA in a single step with capping efficiency often exceeding 95%. Enzymatic capping is performed after IVT and uses three sequential enzymatic activities (RNA triphosphatase, guanylyltransferase, and methyltransferase) to build the cap structure post-transcriptionally. Co-transcriptional capping is simpler and preferred for most therapeutic workflows, while enzymatic capping may be chosen when a native Cap 1 structure is required without cap analog interference.
Q2: Why is N1-methylpseudouridine (m1Ψ) preferred over pseudouridine (Ψ) in therapeutic mRNA?
Both m1Ψ and Ψ reduce innate immune activation compared to unmodified uridine. However, m1Ψ offers two advantages: higher translation efficiency in vivo and improved incorporation fidelity by T7 polymerase. The methyl group at the N1 position prevents mispairing and enhances the thermodynamic stability of the modified base pair, resulting in more consistent protein expression.
Q3: How do I prevent double-stranded RNA (dsRNA) contamination in my IVT reaction?
dsRNA is a common byproduct of IVT and a potent activator of innate immunity. Strategies to minimize it include: (1) using a low-dsRNA T7 polymerase variant such as PrimeCap; (2) optimizing magnesium and NTP concentrations; (3) performing post-IVT purification with RP-HPLC or oligo(dT) chromatography; and (4) designing the DNA template to avoid cryptic promoter sequences that initiate unintended transcription.
Q4: What is the optimal ratio of cap analog to GTP in a co-transcriptional capping reaction?
For CleanCap AG, the recommended concentration is typically 4 mM, while GTP is used at 5 mM—a cap-to-GTP ratio of approximately 0.8:1. For ARCA, a higher cap-to-GTP ratio (e.g., 4:1 or greater) is required because ARCA competes less efficiently with GTP for incorporation at the 5′ end. The optimal ratio should be empirically determined for each template and polymerase preparation.
Q5: Can I use the same IVT reagents for both research-grade and therapeutic-grade mRNA?
No. Research-grade IVT reactions may use wild-type T7 polymerase, unmodified NTPs, and standard buffers. Therapeutic-grade mRNA requires additional considerations: animal-origin-free reagents, m1ΨTP with documented purity, low-dsRNA polymerase, and reagents qualified for GMP-compatible workflows. The buffer composition may also be adjusted to minimize dsRNA formation and maximize capping efficiency.
Q6: How should I store IVT reagents to maintain activity?
RNA polymerase should be stored at −20°C in glycerol-containing buffer and avoided repeated freeze-thaw cycles. NTPs and modified NTPs are best stored at −20°C or −80°C as concentrated stocks, protected from light. Cap analogs are generally stable at −20°C but should be protected from moisture. Buffers and DTT can be stored at −20°C; DTT-containing solutions should be prepared fresh or stored in aliquots to prevent oxidation.
8. Source Materials for Your mRNA Research Workflow
Whether you are developing an IVT reaction, evaluating mRNA purification strategies, screening LNP compositions, or establishing analytical methods, J&K Scientific provides research materials to support key stages of nucleic acid research.
Explore related products or contact our technical sales team for assistance identifying suitable materials for your research and process-development requirements.
艳 李
